The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trial in progress: ENCORE—Multicenter prospective registry of sequential antibody drug conjugates (ADCs) in HER2 negative metastatic breast cancer (MBC) (TBCRC-067).
 
Laura Huppert
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - Greenwich LifeSciences (Inst)
Patents, Royalties, Other Intellectual Property - Book royalties: McGraw Hill
 
Leif Ellisen
Consulting or Advisory Role - AstraZeneca; Atavistik; Gilead Sciences; KisoJi Biotechnology; mersana
Research Funding - Eisai (Inst); Sanofi (Inst)
 
Carey Anders
Honoraria - AstraZeneca; Athenex; Beigene; Elucida Oncology; Genentech/Roche; Immunomedics; Novartis; Seagen
Consulting or Advisory Role - AstraZeneca; Athenex; Beigene; Eisai; Elucida Oncology; Genentech/Roche; Immunomedics; Roche; Seagen
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Caris Life Sciences (Inst); Elucida Oncology (Inst); G1 Therapeutics (Inst); Incyclix Bio (Inst); Lilly (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Zion Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Jones and Bartlett; Up to Date.com
Travel, Accommodations, Expenses - Eisai
 
Claudine Isaacs
Honoraria - Pfizer
Consulting or Advisory Role - AstraZeneca/MedImmune; Genentech/Roche; Gilead Sciences; Merck; Novartis; Pfizer; Puma Biotechnology; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb/Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Elsevier - Editor of Book; McGraw Hill Publishing; UpToDate - Wolters Kluwer - Author of chapters
Travel, Accommodations, Expenses - Pfizer
Other Relationship - Curio/Vaniam Group; Medscape; MJH/PER; Side-Out Foundation
 
Cesar Santa-Maria
Consulting or Advisory Role - Abbvie; Athenex; Bristol-Myers Squibb; Calibr; Calibr; Genomic Health; Halozyme; Immunomic Therapeutics; Merck; Pfizer; Pfizer; Polyphor; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Genentech (Inst); Medimmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Tesaro (Inst)
(OPTIONAL) Uncompensated Relationships - Gilead Sciences; Greenwich LifeSciences
 
Jesus Anampa
No Relationships to Disclose
 
Angela DeMichele
Consulting or Advisory Role - Pfizer (I)
Research Funding - Genentech (Inst); Inivata/NeoGenomics (Inst); Novartis (Inst); Pfizer (Inst)
 
Marija Balic
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Pfizer; Pierre Fabre; Roche; Samsung; Seagen
Speakers' Bureau - Amgen; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Lilly; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - AstraZeneca (Inst); Daichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst)
Travel, Accommodations, Expenses - MSD
 
Jennifer Specht
Honoraria - BioNTech SE; Daiichi Sankyo; SCRIPPS Research Institute; Sensei Biotherapeutics
Consulting or Advisory Role - BioNTech SE; Boehringer Ingelheim; Daiichi Sankyo; GE Healthcare; Lyell Immunopharma Inc
Research Funding - A2 Biotherapeutics (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Biocity (Inst); Carisma Therapeutics (Inst); Celcuity (Inst); Genentech (Inst); Lyell Immunopharma (Inst); Merck (Inst); OnKure (Inst); Pfizer (Inst); Seagen (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - UW CoMotion - Patent Royalty for ROR1 CAR (Inst)
Travel, Accommodations, Expenses - A2 Biotherapeutics; Dava Oncology; GE Healthcare; GlaxoSmithKline; iwCAR-T; Nektar
 
Maryam Lustberg
Honoraria - Novartis
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Lilly; Menarini; Novartis; Osmol Therapeutics; Pfizer
Speakers' Bureau - Lilly
Other Relationship - Cynosure/Hologic
 
Antonio Wolff
Patents, Royalties, Other Intellectual Property - Antonio Wolff has been named as inventor on one or more issued patents or pending patent applications relating to methylation in breast cancer, and has assigned his rights to JHU, and participates in a royalty sharing agreement with JHU.
 
Ian Krop
Employment - PureTech (I)
Leadership - PureTech (I)
Stock and Other Ownership Interests - PureTech (I)
Honoraria - AstraZeneca; Daiichi Sankyo
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Genentech/Roche; Merck; Merck KGaA; Novartis; Seagen
Research Funding - Genentech (Inst); Macrogenics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - anti-murine CD19 monoclonal antibody licensed to PharMingen
 
Hope Rugo
Honoraria - Chugai Pharma; Mylan/Viatris
Consulting or Advisory Role - Bristol Meyer; Napo Pharmaceuticals; Sanofi
Research Funding - Ambryx (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Hoffmann-La Roche AG/Genentech, Inc (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Stemline Therapeutics (Inst)